Directed Change in TNFα Specificity to Create DR5 Antagonists.

Area of Science:

• Oncology
• Molecular Biology
• Immunology

Background:

• Death Receptor 5 (DR5) is highly expressed on tumor cells, making it a key target for cancer therapy.
• Tumor cells often exhibit resistance to TRAIL, a natural DR5 ligand, limiting its therapeutic efficacy.
• Novel agonists are needed to overcome resistance and enhance DR5-mediated antitumor effects.

Purpose of the Study:

• To identify and develop novel agonists that specifically bind and activate Death Receptor 5 (DR5).
• To engineer a modified tumor necrosis factor alpha (TNFα) protein incorporating a DR5-binding peptide for enhanced antitumor activity.
• To evaluate the cytotoxicity of the engineered protein against lymphoma cells.

Main Methods:

• Screening of a combinatorial peptide library to identify DR5-specific binding sequences.
• Engineering of a mutant TNFα protein (TNFα-mut) by incorporating the identified DR5-binding peptide (KVVLTHR).
• Assessment of TNFα-mut binding to DR5 and its resulting cytotoxic effects on lymphoma cell lines.

Main Results:

• A peptide sequence, KVVLTHR, was identified that specifically binds to Death Receptor 5 (DR5).
• Incorporation of KVVLTHR into TNFα resulted in a mutant protein, TNFα-mut, that binds DR5.
• TNFα-mut demonstrated significant cytotoxicity against lymphoma cells, indicating therapeutic potential.

Conclusions:

• The engineered TNFα-mut protein, which binds DR5 via the KVVLTHR peptide, effectively induces cytotoxicity in lymphoma cells.
• This approach offers a promising strategy to overcome TRAIL resistance and enhance DR5-targeted cancer therapy.
• Further development of DR5 agonists could lead to novel treatments for various cancers.